Cargando…

Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma

BACKGROUND: Although anaplastic lymphoma kinase (ALK) is overexpressed in several primary solid tumor types, its role in endometrial carcinoma (Em Ca) remains unclear. METHODS: We evaluated expression of ALK and its related molecules in clinical samples consisting of 168 Em Ca tissues. We also used...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoi, Ako, Nakamura, Yusaku, Hashimura, Miki, Oguri, Yasuko, Matsumoto, Toshihide, Nakagawa, Mayu, Ishibashi, Yu, Ito, Takashi, Ohhigata, Kensuke, Harada, Youhei, Fukagawa, Naomi, Saegusa, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436652/
https://www.ncbi.nlm.nih.gov/pubmed/37592266
http://dx.doi.org/10.1186/s12885-023-11144-2
_version_ 1785092382516051968
author Yokoi, Ako
Nakamura, Yusaku
Hashimura, Miki
Oguri, Yasuko
Matsumoto, Toshihide
Nakagawa, Mayu
Ishibashi, Yu
Ito, Takashi
Ohhigata, Kensuke
Harada, Youhei
Fukagawa, Naomi
Saegusa, Makoto
author_facet Yokoi, Ako
Nakamura, Yusaku
Hashimura, Miki
Oguri, Yasuko
Matsumoto, Toshihide
Nakagawa, Mayu
Ishibashi, Yu
Ito, Takashi
Ohhigata, Kensuke
Harada, Youhei
Fukagawa, Naomi
Saegusa, Makoto
author_sort Yokoi, Ako
collection PubMed
description BACKGROUND: Although anaplastic lymphoma kinase (ALK) is overexpressed in several primary solid tumor types, its role in endometrial carcinoma (Em Ca) remains unclear. METHODS: We evaluated expression of ALK and its related molecules in clinical samples consisting of 168 Em Ca tissues. We also used Em Ca cell lines to evaluate the functional role of ALK. RESULTS: Cytoplasmic ALK immunoreactivity in the absence of chromosomal rearrangement was positively correlated with ALK mRNA expression, and was significantly higher in Grade (G) 3 Em Ca than in G1 or G2 tumors. ALK immunoreactivity was also significantly associated with expression of cancer stem cell (CSC)-related molecules (cytoplasmic CD133, ALDH1, Sox2) and neuroendocrine markers (CD56 and synaptophysin). Although the proliferative index was significantly higher in ALK-positive Em Ca when compared to ALK- negative malignancies, there was no association between ALK expression and other clinicopathological factors in this disease. In Em Ca cell lines, full-length ALK overexpression increased proliferation, decreased susceptibility to apoptosis, enhanced cancer stem cell features, and accelerated cell mobility, whereas these phenotypes were abrogated in ALK-knockdown cells. Finally, patients with tumors harboring either wild-type ALK or high ALK mRNA expression had a poorer prognosis than those with either mutant ALK or low ALK mRNA expression. CONCLUSION: Full-length ALK overexpression occurs in a subset of Em Ca, particularly in G3 tumors, and contributes to the establishment and maintenance of aggressive phenotypic characteristics through modulation of several biological processes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11144-2.
format Online
Article
Text
id pubmed-10436652
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104366522023-08-19 Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma Yokoi, Ako Nakamura, Yusaku Hashimura, Miki Oguri, Yasuko Matsumoto, Toshihide Nakagawa, Mayu Ishibashi, Yu Ito, Takashi Ohhigata, Kensuke Harada, Youhei Fukagawa, Naomi Saegusa, Makoto BMC Cancer Research BACKGROUND: Although anaplastic lymphoma kinase (ALK) is overexpressed in several primary solid tumor types, its role in endometrial carcinoma (Em Ca) remains unclear. METHODS: We evaluated expression of ALK and its related molecules in clinical samples consisting of 168 Em Ca tissues. We also used Em Ca cell lines to evaluate the functional role of ALK. RESULTS: Cytoplasmic ALK immunoreactivity in the absence of chromosomal rearrangement was positively correlated with ALK mRNA expression, and was significantly higher in Grade (G) 3 Em Ca than in G1 or G2 tumors. ALK immunoreactivity was also significantly associated with expression of cancer stem cell (CSC)-related molecules (cytoplasmic CD133, ALDH1, Sox2) and neuroendocrine markers (CD56 and synaptophysin). Although the proliferative index was significantly higher in ALK-positive Em Ca when compared to ALK- negative malignancies, there was no association between ALK expression and other clinicopathological factors in this disease. In Em Ca cell lines, full-length ALK overexpression increased proliferation, decreased susceptibility to apoptosis, enhanced cancer stem cell features, and accelerated cell mobility, whereas these phenotypes were abrogated in ALK-knockdown cells. Finally, patients with tumors harboring either wild-type ALK or high ALK mRNA expression had a poorer prognosis than those with either mutant ALK or low ALK mRNA expression. CONCLUSION: Full-length ALK overexpression occurs in a subset of Em Ca, particularly in G3 tumors, and contributes to the establishment and maintenance of aggressive phenotypic characteristics through modulation of several biological processes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11144-2. BioMed Central 2023-08-17 /pmc/articles/PMC10436652/ /pubmed/37592266 http://dx.doi.org/10.1186/s12885-023-11144-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yokoi, Ako
Nakamura, Yusaku
Hashimura, Miki
Oguri, Yasuko
Matsumoto, Toshihide
Nakagawa, Mayu
Ishibashi, Yu
Ito, Takashi
Ohhigata, Kensuke
Harada, Youhei
Fukagawa, Naomi
Saegusa, Makoto
Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
title Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
title_full Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
title_fullStr Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
title_full_unstemmed Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
title_short Anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
title_sort anaplastic lymphoma kinase overexpression enhances aggressive phenotypic characteristics of endometrial carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436652/
https://www.ncbi.nlm.nih.gov/pubmed/37592266
http://dx.doi.org/10.1186/s12885-023-11144-2
work_keys_str_mv AT yokoiako anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT nakamurayusaku anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT hashimuramiki anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT oguriyasuko anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT matsumototoshihide anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT nakagawamayu anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT ishibashiyu anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT itotakashi anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT ohhigatakensuke anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT haradayouhei anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT fukagawanaomi anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma
AT saegusamakoto anaplasticlymphomakinaseoverexpressionenhancesaggressivephenotypiccharacteristicsofendometrialcarcinoma